Sign In
Buy URGN
$26.60
+0.0600 (+0.226%)
At Close: Jun 03, 2026
Ongoing Securities Investigation into UroGen Pharma Ltd. (URGN) - Contact Levi & Korsinsky
09:30am, Wednesday, 21'st May 2025
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
09:00am, Wednesday, 21'st May 2025
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN).
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky to Protect Your Rights
06:30pm, Tuesday, 20'th May 2025
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
06:06pm, Tuesday, 20'th May 2025
NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ: URGN).
Investigation Alert: UroGen Pharma Ltd. (URGN) Under Scrutiny - Contact Levi & Korsinsky for Details
10:15am, Tuesday, 20'th May 2025
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NAS
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of UroGen Pharma Ltd. (“Ur
Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN) Over Potential Securities Fraud Allegations
02:00pm, Monday, 19'th May 2025
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NAS
UroGen Pharma Ltd. (URGN) Investors Who Lost Money – Contact Law Offices of Howard G.
09:00am, Monday, 19'th May 2025
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) investors concerning the Co
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) on behalf of investors concerning the
INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer & Holzer, LLC
01:59pm, Friday, 16'th May 2025
ATLANTA, May 16, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) complied with federal securities laws. On
UroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call Transcript
01:20pm, Monday, 12'th May 2025
UroGen Pharma Ltd. (NASDAQ:URGN ) Q1 2025 Earnings Conference Call May 12, 2025 10:00 AM ET Company Participants Vincent Perrone - Senior Director, Investor Relations Liz Barrett - President and Chief
Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates
10:15am, Monday, 12'th May 2025
Urogen Pharma (URGN) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.97 per share a year ago.
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
08:00am, Monday, 12'th May 2025
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
